Abstract
In silico (or virtual) screening has become a common practice in current computer-aided drug design efforts. However, application to hit discovery in the G Protein-Coupled Receptors (GPCRs) arena was until recently hampered by the paucity of crystal structures available for this important class of pharmaceutical targets, forcing practitioners in the field to rely on GPCR models derived either ab initio or through homology modeling approaches. In this work we describe the EPIX in silico screening workflow which consists of the following stages: (1) Target modeling; (2) Preparation of screening library; (3) Docking; (4) Binding mode selection; (5) Scoring; (6) Consensus scoring and (7) Selection of virtual hits. This workflow was applied to the virtual screening of 13 GPCRs (5 biogenic amine receptors, 5 peptide receptors, 1 lipid receptor, 1 purinergic receptor and 1 cannabinoid receptor). Hit rates vary between 4% and 21% with higher hit rates usually obtained for biogenic amines and lower hits rates for peptide receptors. These data are analyzed in the context of the available experimental information (i.e., mutational data), the model (i.e., binding site location, and type of interactions) and the screening library. Specific examples are discussed in more detail as well as the future directions and challenges of this approach to in silico screening.
Keywords: GPCRs, PREDICT, In silico screening, virtual screening, structure-based drug design, docking
Current Pharmaceutical Design
Title: G Protein-Coupled Receptors: Target-Based In Silico Screening
Volume: 15 Issue: 35
Author(s): Hanoch Senderowitz and Yael Marantz
Affiliation:
Keywords: GPCRs, PREDICT, In silico screening, virtual screening, structure-based drug design, docking
Abstract: In silico (or virtual) screening has become a common practice in current computer-aided drug design efforts. However, application to hit discovery in the G Protein-Coupled Receptors (GPCRs) arena was until recently hampered by the paucity of crystal structures available for this important class of pharmaceutical targets, forcing practitioners in the field to rely on GPCR models derived either ab initio or through homology modeling approaches. In this work we describe the EPIX in silico screening workflow which consists of the following stages: (1) Target modeling; (2) Preparation of screening library; (3) Docking; (4) Binding mode selection; (5) Scoring; (6) Consensus scoring and (7) Selection of virtual hits. This workflow was applied to the virtual screening of 13 GPCRs (5 biogenic amine receptors, 5 peptide receptors, 1 lipid receptor, 1 purinergic receptor and 1 cannabinoid receptor). Hit rates vary between 4% and 21% with higher hit rates usually obtained for biogenic amines and lower hits rates for peptide receptors. These data are analyzed in the context of the available experimental information (i.e., mutational data), the model (i.e., binding site location, and type of interactions) and the screening library. Specific examples are discussed in more detail as well as the future directions and challenges of this approach to in silico screening.
Export Options
About this article
Cite this article as:
Senderowitz Hanoch and Marantz Yael, G Protein-Coupled Receptors: Target-Based In Silico Screening, Current Pharmaceutical Design 2009; 15 (35) . https://dx.doi.org/10.2174/138161209789824821
DOI https://dx.doi.org/10.2174/138161209789824821 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology The Complex Inter-Relationship Between Diabetes and Schizophrenia
Current Diabetes Reviews Analytic strategies to evaluate the association of time-varying exposures to HIV-related outcomes: Alcohol consumption as an example
Current HIV Research Directed Functional Connectivity of Posterior Cingulate Cortex and Whole Brain in Alzheimer's Disease and Mild Cognitive Impairment
Current Alzheimer Research NAP Protects against Tau Hyperphosphorylation Through GSK3
Current Pharmaceutical Design Editorial [Hot Topic: Anti-Amyloidogenic/Protein-Misfolding Therapies in Amyloidosis and Other Protein-Misfolding Disorders (Executive Editor: Masahito Yamada)]
Current Pharmaceutical Design Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer’s Disease and Depression
Current Medicinal Chemistry The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments
Mini-Reviews in Medicinal Chemistry Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews Drugs and Foods for Chronic Subclinical Inflammation in Humans
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Subject Index To Volume 6
Central Nervous System Agents in Medicinal Chemistry Kinetics of In Vitro Inhibition of Acetylcholinesterase by Nineteen New Carbamates
Current Enzyme Inhibition Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine “The Future Magic Bullet”: A Review of Pharmacological Activities of Ethyl Pyruvate and its Derivatives
Current Drug Therapy Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
Current Pharmaceutical Design Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology Intestinal Absorption and Presystemic Elimination of Various Chemical Constituents Present in GBE50 Extract, a Standardized Extract of Ginkgo biloba Leaves
Current Drug Metabolism Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets